Glucocorticoid therapy does not delay viral clearance in COVID-19 patients.
作者信息
Ji Jingjing, Zhang Jinxia, Shao Ziyun, Xie Qifeng, Zhong Li, Liu Zhifeng
机构信息
Department of Critical Care Medicine, General Hospital of Southern Theater Command of PLA, Guangzhou, 510010, China.
Cardiovascular Department, General Hospital of Southern Theater Command of PLA, Guangzhou, 510010, China.
出版信息
Crit Care. 2020 Sep 21;24(1):565. doi: 10.1186/s13054-020-03287-6.
Abstract
摘要
相似文献
1
Glucocorticoid therapy does not delay viral clearance in COVID-19 patients.糖皮质激素治疗不会延迟COVID-19患者的病毒清除。
Crit Care. 2020 Sep 21;24(1):565. doi: 10.1186/s13054-020-03287-6.
2
Persistence and clearance of viral RNA in 2019 novel coronavirus disease rehabilitation patients.新冠康复患者体内病毒 RNA 的持续存在与清除。
Chin Med J (Engl). 2020 May 5;133(9):1039-1043. doi: 10.1097/CM9.0000000000000774.
3
[Glucocorticoid for coronavirus disease 2019: a dilemma].[2019冠状病毒病的糖皮质激素治疗：一个两难困境]
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2020 Mar;32(3):278. doi: 10.3760/cma.j.cn121430-20200309-00352.
4
Glucocorticoid-Induced Bacterial Endocarditis in COVID-19 Pneumonia - Something to Be Concerned About?新冠病毒肺炎中糖皮质激素诱导的细菌性心内膜炎——值得关注吗？
Circ J. 2020 Sep 25;84(10):1887. doi: 10.1253/circj.CJ-20-0462. Epub 2020 Aug 7.
5
BET 2: Hydroxychloroquine in the treatment of COVID-19.BET 2：羟氯喹治疗2019冠状病毒病
Emerg Med J. 2020 Jul;37(7):451-453. doi: 10.1136/emermed-2020-210221.3.
6
A Challenging Colectomy for Acute Severe Ulcerative Colitis Complicated by COVID-19.一例因新型冠状病毒肺炎（COVID-19）并发急性重症溃疡性结肠炎而进行的具有挑战性的结肠切除术
Inflamm Bowel Dis. 2020 Sep 18;26(10):e120-e122. doi: 10.1093/ibd/izaa186.
7
Dexamethasone in the management of covid -19.地塞米松在新冠病毒病治疗中的应用
BMJ. 2020 Jul 3;370:m2648. doi: 10.1136/bmj.m2648.
8
SARS-CoV-2 RNAemia in a Healthy Blood Donor 40 Days After Respiratory Illness Resolution.一名健康献血者在呼吸道疾病痊愈40天后出现新冠病毒血症
Ann Intern Med. 2020 Nov 17;173(10):853-854. doi: 10.7326/L20-0725. Epub 2020 Jul 17.
9
COVID-19: The Uninvited Guest in the Intensive Care Unit - Implications for Pharmacotherapy.新型冠状病毒肺炎：重症监护病房中的不速之客——对药物治疗的影响
Pharmacotherapy. 2020 May;40(5):382-386. doi: 10.1002/phar.2394. Epub 2020 May 4.
10
Factors Associated With Prolonged Viral RNA Shedding in Patients with Coronavirus Disease 2019 (COVID-19).2019冠状病毒病（COVID-19）患者病毒RNA长期脱落的相关因素
Clin Infect Dis. 2020 Jul 28;71(15):799-806. doi: 10.1093/cid/ciaa351.
引用本文的文献
1
Efficacy of azvudine plus dexamethasone in severe hospitalized patients with Omicron infection: a prospective multicenter study.阿兹夫定联合地塞米松治疗奥密克戎感染重症住院患者的疗效：一项前瞻性多中心研究
Front Cell Infect Microbiol. 2024 Nov 22;14:1390098. doi: 10.3389/fcimb.2024.1390098. eCollection 2024.
2
Early Versus Delayed Usage of Paxlovid in Severe Omicron-Infected Patients With Hypoxemia: A Prospective Multiple-Center Cohort Study.帕罗韦德在重度低氧血症奥密克戎感染患者中的早期与延迟使用：一项前瞻性多中心队列研究
Health Sci Rep. 2024 Nov 11;7(11):e70177. doi: 10.1002/hsr2.70177. eCollection 2024 Nov.
3
Estimation of shedding time in laboratory-confirmed COVID-19 cases in South Africa: a population-based record linkage study, March-December 2020.南非基于人群的病例关联研究估算实验室确诊的 2019 冠状病毒病病例的脱落时间：2020 年 3 月至 12 月。
Pan Afr Med J. 2023 Sep 15;46:24. doi: 10.11604/pamj.2023.46.24.41047. eCollection 2023.
4
Efficacy and Safety Comparison of Two Different Doses of Dexamethasone in Hospitalized Patients with COVID-19: A Randomized Clinical Trial.两种不同剂量地塞米松对 COVID-19 住院患者的疗效与安全性比较：一项随机临床试验
J Res Pharm Pract. 2023 Aug 29;11(4):136-143. doi: 10.4103/jrpp.jrpp_42_22. eCollection 2022 Oct-Dec.
5
Fighting cytokine storm and immunomodulatory deficiency: By using natural products therapy up to now.对抗细胞因子风暴和免疫调节缺陷：截至目前采用天然产物疗法。
Front Pharmacol. 2023 Apr 12;14:1111329. doi: 10.3389/fphar.2023.1111329. eCollection 2023.
6
Estimate and determinants of SARS-CoV-2 RNA clearance time among non-severe COVID-19 patients.非重症COVID-19患者中SARS-CoV-2 RNA清除时间的估计及其决定因素
J Family Med Prim Care. 2022 May;11(5):1890-1897. doi: 10.4103/jfmpc.jfmpc_1841_21. Epub 2022 May 14.
7
C-reactive protein cut-off for early tocilizumab and dexamethasone prescription in hospitalized patients with COVID-19.新冠住院患者早期使用托珠单抗和地塞米松处方的C反应蛋白临界值
Sci Rep. 2022 Mar 28;12(1):5250. doi: 10.1038/s41598-022-08882-x.
8
Association between glucocorticoids treatment and viral clearance delay in patients with COVID-19: a systematic review and meta-analysis.糖皮质激素治疗与 COVID-19 患者病毒清除延迟的关系：系统评价和荟萃分析。
BMC Infect Dis. 2021 Oct 14;21(1):1063. doi: 10.1186/s12879-021-06548-z.
9
Nonsteroidal anti-inflammatory drugs and glucocorticoids in COVID-19.非甾体类抗炎药和糖皮质激素在 COVID-19 中的应用。
Adv Biol Regul. 2021 Aug;81:100818. doi: 10.1016/j.jbior.2021.100818. Epub 2021 Jul 15.
10
Risk factors for mortality in critically ill patients with COVID-19: a multicenter retrospective case-control study.COVID-19 重症患者死亡的危险因素：一项多中心回顾性病例对照研究。
BMC Infect Dis. 2021 Jun 24;21(1):602. doi: 10.1186/s12879-021-06300-7.
本文引用的文献
1
Low-dose corticosteroid therapy does not delay viral clearance in patients with COVID-19.低剂量皮质类固醇疗法不会延迟新冠病毒疾病患者的病毒清除。
J Infect. 2020 Jul;81(1):147-178. doi: 10.1016/j.jinf.2020.03.039. Epub 2020 Apr 11.
2
The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China.抗炎药物在治疗重症新型冠状病毒病 2019（COVID-19）患者中的应用：来自中国临床免疫学家的观点。
Clin Immunol. 2020 May;214:108393. doi: 10.1016/j.clim.2020.108393. Epub 2020 Mar 25.
3
Persistence and clearance of viral RNA in 2019 novel coronavirus disease rehabilitation patients.新冠康复患者体内病毒 RNA 的持续存在与清除。
Chin Med J (Engl). 2020 May 5;133(9):1039-1043. doi: 10.1097/CM9.0000000000000774.
Zotero 插件